Featured Research

from universities, journals, and other organizations

New Combination Therapy Safe, Promising For Melanoma Patients

Date:
June 3, 2008
Source:
University of Pittsburgh Medical Center
Summary:
Researchers in the melanoma and skin cancer program at the University of Pittsburgh Cancer Institute combined two biotherapies, high-dose interferon alfa-2b and tremelimumab, and found the combination may be beneficial for patients with inoperable melanoma. The study has since moved into the second stage, where it will enroll 21 additional patients.

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Related Articles


Researchers in the melanoma and skin cancer program at UPCI combined two biotherapies -- treatments that stimulate the immune system to fight cancer -- and found the results promising in terms of anti-tumor effects and tolerable in terms of toxicity. High-dose interferon alfa-2b, a standard treatment for metastatic skin cancer, and tremelimumab, an antibody thought to instigate the body's immune system to attack tumors, were combined for the first time in this phase 2 clinical trial.

"With each new study, we learn something important about melanoma," said John M. Kirkwood, M.D., leader of the program and professor and vice chairman for clinical research in the Department of Medicine, University of Pittsburgh School of Medicine. "With this study, we learned that adding tremelimumab to traditional treatment is not only safe, but an effective way to induce an anti-tumor response, which is very exciting."

For this study, 16 patients diagnosed with stage 4 melanoma, all of whom received and had not benefited from at least one round of previous therapy, were given the combination treatment. The overall response rate was 19 percent, and the study has since moved into the second stage, where it will enroll 21 additional patients.

Melanoma is a rare form of skin cancer, but it causes the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide, and currently surgery is the only effective cure. For patients with inoperable disease, like those enrolled in this study, discovering a safe and effective treatment is vital.

Ahmad Tarhini, M.D., assistant professor at the University of Pittsburgh School of Medicine and lead author of this study, will give the accompanying oral presentation at 10:15 a.m., June 1. Other investigators include S.S. Moschos, M.D.; J.J. Schelsselman, Ph.D.; J. Shipe-Spotloe, P.A.; M. Denmark, all of UPCI.

The study is published as abstract number 9009 in the 2008 ASCO Annual Meeting Proceedings.


Story Source:

The above story is based on materials provided by University of Pittsburgh Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Pittsburgh Medical Center. "New Combination Therapy Safe, Promising For Melanoma Patients." ScienceDaily. ScienceDaily, 3 June 2008. <www.sciencedaily.com/releases/2008/06/080601161833.htm>.
University of Pittsburgh Medical Center. (2008, June 3). New Combination Therapy Safe, Promising For Melanoma Patients. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2008/06/080601161833.htm
University of Pittsburgh Medical Center. "New Combination Therapy Safe, Promising For Melanoma Patients." ScienceDaily. www.sciencedaily.com/releases/2008/06/080601161833.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins